Abstract
The article discusses the pathogenetic and clinical aspects of gastrointestinal bleeding (GIB) in patients with a novel coronavirus infection (COVID-19). The possibility of direct interaction of the coronavirus with the receptors of the angiotensinconverting enzyme 2 (ACE-2) of the mucous membrane of the gastrointestinal tract with the development of its damage and subsequent bleeding has been shown. The value of anticoagulant therapy as a risk factor for the occurrence of GIB is evaluated inconsistently. In most patients with COVID-19 infection and GIB conservative hemostatic therapy is eff ective. The infl uence of GIB on the course and prognosis of a novel coronavirus infection has an contradictory interpretation. Given the lack of knowledge of the pathogenetic and clinical aspects of GIB in patients with COVID-19 infection, this problem requires further research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
